Castration-resistant prostate cancer exhibits resistance to androgen deprivation therapy mainly because IL-23 secreted by MDSCs activates the androgen receptor (AR) and the STAT3/RORγ signaling axis in prostate tumor cells. The gene discussed is AR; the disease is prostate neoplasm.